Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $225,000.00 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 2,250 shares of Blueprint Medicines stock in a transaction on Monday, January 13th. The stock was sold at an average price of $100.00, for a total transaction of $225,000.00. Following the transaction, the insider now directly owns 14,967 shares of the company’s stock, valued at $1,496,700. This represents a 13.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Ariel Hurley also recently made the following trade(s):

• On Thursday, December 12th, Ariel Hurley sold 1,819 shares of Blueprint Medicines stock. The stock was sold at an average price of $93.26, for a total value of $169,639.94.

Blueprint Medicines Stock Up 5.9 %

BPMC stock opened at $110.05 on Friday. The stock’s 50 day moving average is $94.09 and its 200-day moving average is $95.42. Blueprint Medicines Co. has a twelve month low of $72.24 and a twelve month high of $121.90. The firm has a market capitalization of $6.99 billion, a PE ratio of -52.16 and a beta of 0.61. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. The firm had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business’s revenue for the quarter was up 126.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($2.20) EPS. Sell-side analysts expect that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Guggenheim reissued a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. UBS Group assumed coverage on Blueprint Medicines in a research note on Thursday, October 24th. They issued a “neutral” rating and a $88.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and set a $124.00 price objective (down previously from $135.00) on shares of Blueprint Medicines in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, November 15th. Finally, JMP Securities reissued a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $122.72.

Institutional Investors Weigh In On Blueprint Medicines

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Federated Hermes Inc. grew its holdings in shares of Blueprint Medicines by 27.8% in the second quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company’s stock valued at $6,721,000 after acquiring an additional 13,579 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new position in Blueprint Medicines in the second quarter worth $18,273,000. Citizens Financial Group Inc. RI purchased a new stake in shares of Blueprint Medicines during the 2nd quarter valued at $423,000. Renaissance Technologies LLC raised its stake in shares of Blueprint Medicines by 132.4% during the 2nd quarter. Renaissance Technologies LLC now owns 110,400 shares of the biotechnology company’s stock worth $11,899,000 after purchasing an additional 62,900 shares during the period. Finally, Edgestream Partners L.P. purchased a new position in shares of Blueprint Medicines in the 2nd quarter worth about $1,113,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.